Newsletter Tool

Today’s Big News

Jul 15, 2024

Artiva sets out $135M IPO plans to push NK cell therapy through trials

Destiny goes private to stay afloat after no partner found for anti-infection drug

Lexeo links gene therapy to improvements in rare heart disease but disappoints investors

J&J’s CAR-T partner Legend Biotech reportedly receives buyout offer

Regulatory tracker: Roche's subcutaneous Ocrevus nabs UK approval

Featured

Artiva sets out $135M IPO plans to push NK cell therapy through trials

By James Waldron

Artiva Biotherapeutics is hoping to rake in up to $135 million from a planned IPO, with the proceeds ear-marked for automimmune clinical trials for a lead allogeneic natural killer (NK) cell therapy.

Destiny goes private to stay afloat after no partner found for anti-infection drug

By James Waldron

Destiny Pharma’s search for a partner to take its nasal infection prevention med into phase 3 has come up short, leading the British biotech to go private to avoid liquidation.

Lexeo links gene therapy to improvements in rare heart disease but disappoints investors

By Nick Paul Taylor

Lexeo Therapeutics has guided its Friedreich ataxia (FA) gene therapy through an early test, generating evidence of improvements in cardiac status in early-phase trials. But the biotech ran into problems when testing the effect of the candidate on fitness and was left with a gap in evidence.

J&J’s CAR-T partner Legend Biotech reportedly receives buyout offer

By Angus Liu

CAR-T specialist Legend Biotech has reportedly received a takeover bid and has tapped Centerview Partners as a financial adviser to evaluate its options. The news led to a surge in the stock price of the company and its parent GenScript.

Regulatory tracker: Roche's subcutaneous Ocrevus nabs UK approval

By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy

In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.

Netflix and ill: ‘Supacell’ taps streaming giant for ‘super’ sickle cell awareness

By Ben Adams

Sickle cell disease (SCD) is a serious, life-long, and potentially life-limiting disease that predominately affects the Black community, but awareness of this disease remains low.

Edwards Lifesciences nabs mitral valve startup Innovalve for $300M

By Conor Hale

After previously backing the startup, Edwards Lifesciences is exercising its option to acquire Innovalve and its mitral valve replacement implant that literally tugs at the heart strings.

Fierce podcasts

Don’t miss an episode

A look at Big Pharma’s top-paid CEOs

In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky and Fraiser Kansteiner discuss Fierce’s annual special report, “Big Pharma's 10 highest-paid CEOs.”

The state of digital health investment in 2024

The best biopharma M&A deals

Resources

Whitepaper

An Integrated End-to-End Approach to Antibody Drug Conjugate Development and Manufacturing

In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.

The “Best Practice Organization” & Its Importance for Success in Today’s Biopharma Industry

In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers.

Sponsored by: Blue Matter, strategic consultants in the life sciences